Avior Wealth Management LLC decreased its position in STERIS plc (NYSE:STE – Free Report) by 11.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,036 shares of the medical equipment provider’s stock after selling 133 shares during the period. Avior Wealth Management LLC’s holdings in STERIS were worth $251,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in the company. Ashton Thomas Securities LLC acquired a new position in STERIS in the third quarter worth $25,000. Central Pacific Bank Trust Division bought a new position in shares of STERIS in the 3rd quarter worth about $28,000. Quent Capital LLC boosted its holdings in shares of STERIS by 112.7% in the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares during the period. Versant Capital Management Inc grew its position in shares of STERIS by 2,262.5% during the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 181 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its stake in STERIS by 154.7% during the second quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares during the period. 94.69% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently commented on STE shares. KeyCorp upped their target price on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Finally, Stephens restated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.00.
STERIS Stock Down 0.7 %
STERIS stock opened at $214.34 on Friday. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24. The stock has a market cap of $21.16 billion, a price-to-earnings ratio of 48.94 and a beta of 0.85. The company’s 50-day moving average price is $227.89 and its two-hundred day moving average price is $228.49. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33.
STERIS (NYSE:STE – Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $2.12 by $0.02. The firm had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.03 earnings per share. On average, analysts expect that STERIS plc will post 9.15 EPS for the current fiscal year.
STERIS Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.06%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s payout ratio is currently 52.05%.
Insiders Place Their Bets
In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This represents a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.14% of the stock is owned by company insiders.
STERIS Profile
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- How to Choose Top Rated Stocks
- Tesla Investors Continue to Profit From the Trump Trade
- Ride Out The Recession With These Dividend Kings
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Compound Interest and Why It Matters When Investing
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.